Mental health clinic chain Smart TMS has completed a UK-wide research project to...
- Prescription dread: measuring psychiatric drugs against the alternatives
- Real world data: how can it improve clinical trial outcomes?
- US opioid crisis: charting Insys’ fall from grace
- Amgen and Novartis discontinue Alzheimer’s drug development programme
- CAR-T therapy: navigating the US reimbursement landscape
Prescription dread: measuring psychiatric drugs against the alternatives
Mental health clinic chain Smart TMS has completed a UK-wide research project to answer some key questions about attitudes to psychiatric drugs. The company’s medical director and consultant psychiatrist Dr Leigh Neal explains these attitudes to pharmaceutical treatment for mental health conditions, as well as exploring the suitability of brain stimulation techniques as an alternative.
Real world data: how can it improve clinical trial outcomes?
In a world where data is crucial, scientists are increasingly looking beyond the confines of a traditional clinical trial, as was proven recently by the first FDA approval of a drug based purely on real world data. But how can such data be used, and can regulators be convinced by the results?
ETO Sterilisers Brochure
RSD designs and manufactures ethylene oxide (EO) sterilisers for the sterilisation of thermosensitive products (those that are sensitive to heat and humidity) such as syringes, catheters, dialysis cartridges, plastic dressings and sutures.
UK to set up freight service for medicines supply post Brexit
The UK Department of Health and Social Care has announced a £25m contract for express freight service to deliver medicines and medical products after the country exits the European Union (EU).
US Senator seeks records linked to Novartis’ Zolgensma data issues
The US Senate Finance Committee Chairman Chuck Grassley has asked Novartis to provide information on data manipulation issues related to the company’s subsidiary AveXis’ spinal muscular atrophy (SMA) drug Zolgensma.
Sonnet BioTherapeutics agrees to buy Relief Therapeutics
Biotechnology company Sonnet BioTherapeutics has agreed to acquire all outstanding shares of Relief Therapeutics under a binding share exchange agreement with Relief Therapeutics Holding.
US court rules in favour of Amgen in Enbrel patent case
The US District Court for the District of New Jersey has upheld two of Amgen’s patents that claim its rheumatoid arthritis drug Enbrel (etanercept) and methods for making the medicine.
Vaccines Manufacturing Innovation Centre, Oxfordshire
Vaccine Manufacturing Innovation Centre (VMIC) in Oxfordshire will become the first-ever facility dedicated to the development and manufacturing of vaccines in the UK, upon its completion.
Mapi Pharma’s Sterile Injectable Production Plant in Jerusalem
Israel-based clinical-stage pharmaceutical company Mapi Pharma has announced the development of a new sterile injectable production plant in Jerusalem.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.